Validation of Analytical Methods for Drugs: Guidance on Validation in accordance with ICH Q2(R2) and Q14
The quality, safety, and efficacy of a pharmaceutical product depend to a large extent on the reliability of the analytical methods used to evaluate it. The more accurately the active ingredient content, impurity profile, or dissolution rate of a drug is measured, the more sound the decisions regarding the product will be. For this reason , method validation is the cornerstone of pharmaceutical quality control.
As part of international harmonization, the ICH Q2(R2) and the newly published ICH Q14 guidelines specify how analytical methods must be validated and developed. In this article, we will discuss the fundamental parameters of analytical method validation, the current approaches outlined in the ICH guidelines, and Nano-Test’s GLP-compliant services in this area.
What is the validation of analytical methods, and why is it necessary?
The validation of analytical methods refers to the totality of systematic work performed to demonstrate the suitability of an analytical procedure for its intended purpose. A method is considered “valid” only after validation is complete and its performance parameters meet the acceptance criteria.
Validation is required in the following cases:
- Development of New Methods: When a new analytical method is used for the first time,
- Method Transfer: When transferring a method from one laboratory to another,
- Method Modification: When changes are made to an existing method,
- Pharmacopoeia Compliance: For methods to be used in the marketing authorization application,
- Routine quality control: When continuous verification of the method's performance is required.
Results obtained using a method that has not been validated will not be accepted by regulatory authorities and may lead to the rejection of the marketing authorization application.
Validation parameters under ICH Q2(R2)
ICH Q2(R2) defines the basic parameters that must be evaluated during the validation of analytical methods. The parameters required depend on the purpose of the method (identification, quantification, determination of impurities).
1. Accuracy
Refers to how close the measured value is to the actual value. It is typically evaluated using recovery studies and should fall within the range of 98–102%.
2. Precision
It is evaluated on three levels: repeatability, intermediate precision, and reproducibility. The RSD (relative standard deviation) should generally be less than 2%.
3. Specificity
The method's ability to accurately measure the analyte despite the presence of impurities, matrix components, and degradation products. It is evaluated through forced degradation experiments.
4. Limit of Detection (LOD) and Limit of Quantification (LOQ)
The LOD is the lowest concentration that can be detected using the method; the LOQ is the lowest concentration that can be reliably quantified. They are determined based on the signal-to-noise ratio (S/N) or the standard deviation.
5. Linearity and Measurement Range
Specifies the concentration range within which the method responds linearly. The correlation coefficient (R²) should generally be greater than 0.999.
6. Robustness
Indicates the method's resistance to minor experimental variations (pH, temperature, flow rate, column batch).
The Need for Validation Parameters Depending on the Intended Use of the Method
The following table summarizes which validation parameters are required under ICH Q2(R2) for each intended use of the method:
| Validation Parameters | Identification | Quantitative Determination (Assay) | Determination of Impurities | Dissolution rate |
|---|---|---|---|---|
| Accuracy | — | ✓ | ✓ | ✓ |
| Precision | — | ✓ | ✓ | ✓ |
| Specificity | ✓ | ✓ | ✓ | ✓ |
| LOD / LOQ | — | — | ✓ | — |
| Linearity | — | ✓ | ✓ | ✓ |
| Area | — | ✓ | ✓ | ✓ |
| Stability | — | ✓ | ✓ | ✓ |
ICH Q14: “Quality by Design” (QbD) in the Development of Analytical Methods
ICH Q14, which took effect in 2023, introduced the “Quality by Design (QbD)” approach into the analytical method development process. This guideline offers new concepts that complement and reinforce the traditional validation approach:
- Analytical Target Profile (ATP): A preliminary definition of the performance requirements for the method.
- Critical Method Parameters (CMP): Identification of the factors that influence method performance.
- Method's Operational Design Range (MODR): Definition of the parameter range within which the method operates reliably.
- Risk Assessment: A systematic evaluation of the impact of methodological variables on the results.
ICH Q14 emphasizes that validation is not merely a “checklist,” but a process that requires a scientific understanding of the method. This approach ensures that the method is more robust in routine use and that unexpected problems can be identified in advance.
GLP-compliant services for the validation of analytical methods with Nano-Test
The analytical methods for your pharmaceutical products form the basis for your marketing authorization application and your routine quality control. With its GLP-compliant validation services in accordance with ICH Q2(R2) and Q14, Nano-Test is a reliable solution partner for the pharmaceutical industry.
Nano-Test – Statement of Work
Nano-Test offers analytical method validation services for the pharmaceutical industry. In our laboratories, which are accredited according to GLP and ISO/IEC 17025, we perform work that is fully compliant with ICH Guidelines Q2(R2) and Q14.
Our Service Portfolio:
- Method Development: ICH Q14-compliant, systematic method development, including ATP and MODR definitions.
- Validation studies: Evaluation of all parameters with regard to trueness, accuracy, specificity, LOD/LOQ, linearity, measurement range, and robustness.
- Forced Degradation: Studies under acidic, basic, oxidative, thermal, and light stress conditions to evaluate specificity.
- Method Transfer: Cross-laboratory method transfer and comparative validation.
- Method Verification: Verification of pharmacopoeia methods prior to routine use.
- Reporting: Validation reports in CTD format, with test approval and acceptable to regulatory authorities.
We use state-of-the-art equipment such as HPLC-DAD, LC-MS/MS, GC-MS/MS, and ICP-MS in our analyses.
The advantages of Nano-Test in analytical validation:
- Proficiency in current guidelines: Full compliance with the requirements of ICH Q2(R2) and Q14.
- GLP-certified infrastructure: All work is conducted in accordance with GLP principles and ALCOA+ requirements.
- A wide range of technical expertise: HPLC, GC, LC-MS/MS, ICP-MS, and spectroscopic methods—all under one roof.
- CTD-compliant reporting: Complete validation dossiers in accordance with the requirements of Module 3.
- Quick Response: Results within 10–15 business days for standard validation work.
- Expert Team: A team of experienced chemists specializing in analytical chemistry and validation.
The validation of analytical methods forms the basis for all data demonstrating the quality and safety of pharmaceutical products. Validation work conducted in accordance with ICH Q2(R2) scientifically demonstrates the method’s suitability for its intended purpose, while the quality by design approach introduced by ICH Q14 enables a deeper understanding of the method and ensures its robustness in routine use.
With its infrastructure fully aligned with current ICH guidelines, advanced analytical technologies, and GLP-certified processes, Nano-Test fully meets pharmaceutical manufacturers’ requirements for analytical validation. Partner with Nano-Test to expedite your regulatory submission and document the reliability of your analytical methods.